DOI:
10.1055/s-00000133
Gastroenterologie up2date
LinksClose Window
References
Feagan BG, Sandborn WJ, DʼHaens G. et al.
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohnʼs disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet (epub ahead of print April 17, 2017).
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.